Overview:

• vaccine had acceptable safety findings and induced high immune responses
• safe for all people as seen in the study from 5 months to 85 years old
• acceptable candidate to move into Phase 3

Limitations:

• small sample size of the trial
• lack of ethnic diversity
• age was on the younger side
• follow up was short
• participants were generally in good health

Matrix M1 benefit:

• after the second vaccination, neutralizing antibody response was greater than seen in symptomatic covid patients
• the magnitude of antibody and Tcell response
• induction of functional antibodies
• antigen dose sparing
• the two doses of rSARS-CoV-2 with the added Matrix M1 regimen is the best from this clinical trial

Microneutralization testing:

• the vaccine worked as seen with the anti-spike IgG and microneutralization
• anti-spike IgG and microneutralization titers levels can be correlated to the severity of the disease